Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02532764 · ClinicalTrials.gov registry record · Phase 1

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

A Phase 1 study, sponsored by ProQR Therapeutics.

Completed
Registry status
Phase 1
Development phase
70
Enrollment target

NCT02532764: Completed Phase 1 study, sponsored by ProQR Therapeutics.

NCT02532764 is a Phase 1 study that has completed, run by ProQR Therapeutics. The registered enrollment target is 70 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02532764, a Phase 1 study, has completed, sponsored by ProQR Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
70 participants
Enrollment target

Study Summary

A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.

Primary Outcome

Number of subjects experiencing at least one treatment emergent adverse events (TEAEs)

Interventions

  • DRUG Placebo
  • DRUG QR-010

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2015-06
Est. Completion 2017-09-14
Phase Phase 1
ProQR Therapeutics

5 total trials

What the finished NCT02532764 record still lists

NCT02532764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02532764 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02532764 about?

NCT02532764 is a clinical study titled "Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients". A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.

What is the current status of trial NCT02532764?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2015-06. Estimated completion is 2017-09-14.

What interventions are being tested in trial NCT02532764?

The interventions under investigation include: Placebo (DRUG), QR-010 (DRUG).

Who is sponsoring clinical trial NCT02532764?

This trial is sponsored by ProQR Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02532764's enrollment target sits among peer trials

70 749th of 2000 higher than 1,227 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02532764, the US trial registry maintained by the National Library of Medicine. NCT02532764 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.